Posted by Michael Wonder on 26 Apr 2023
Celltrion seeks approval for Xolair biosimilar in EU
25 April 2023 - Celltrion said it has completed a marketing authorization application for CT-P39, a biosimilar referencing Xolair (omalizumab) to the EMA.
Xolair, the original drug, is an antibody biologic developed by Genentech and Novartis for the treatment of allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic idiopathic urticaria.
